Print Page    Close Window

2019 Press Releases

May-06-2019

Protalix BioTherapeutics Reports 2019 First Quarter Results and Provides Corporate Update

CARMIEL, Israel, May 06, 2019 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE:PLX), a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx®, today announced its financial results for the three months ended March 31, 2019 and provided a corporate update. “In the first three months of 2019, we have continued to execute on enrollme... 
Apr-29-2019

Protalix BioTherapeutics to Hold First Quarter 2019 Financial Results and Corporate Update Conference Call on May 6, 2019

CARMIEL, Israel, April 29, 2019 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE American:PLX, TASE:PLX), a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx®, today announced that it will report first quarter 2019 financial results and provide a corporate update on Monday, May 6, 2019 at 8:30 am ET. To participate in the conference call, pleas... 
Mar-18-2019

Protalix BioTherapeutics Reports 2018 Full Year Results and Provides Corporate Update

CARMIEL, Israel, March 18, 2019 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE:PLX), a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx®, today announced its financial results for the full-year ended December 31, 2018 and provided a corporate update. “Throughout 2018 and into early 2019, we significantly advanced our clin... 
Mar-13-2019

Protalix BioTherapeutics to Postpone the 2018 Financial Results and Corporate Update Conference Call

CARMIEL, Israel, March 13, 2019 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE American:PLX, TASE:PLX), a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx®, today announced that it will postpone its 2018 financial results corporate update from Thursday, March 14, 2019, to Monday, March 18, 2019 at 8:30 am ET. To participate in the conference... 
Mar-06-2019

Protalix BioTherapeutics to Hold Full-Year 2018 Financial Results and Corporate Update Conference Call on March 14, 2019

CARMIEL, Israel, March 06, 2019 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE American:PLX, TASE:PLX), a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx®, today announced that it will report full-year 2018 financial results and provide a corporate update on Thursday, March 14, 2019 at 8:30 am ET. To participate in the conference call, please... 
Feb-05-2019

Protalix BioTherapeutics Presents Preliminary Data from the BRIGHT Study of pegunigalsidase alfa for the Treatment of Fabry Disease at the 15th Annual WORLDSymposium™ 2019

~Pharmacokinetic data from patients treated in the study show that infusion of pegunigalsidase alfa every 4 weeks results in the presence of continuous active enzyme throughout the entire infusion interval~ ~Continuous presence and activity of pegunigalsidase alfa detected even in patients with pre-existing anti-drug antibodies~ ~Pegunigalsidase alfa is safe and well tolerated~ CARMIEL, Israel, Feb. 05, 2019 (GLOBE NEWSWIRE) --  Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE:PLX),... 
Jan-28-2019

Protalix BioTherapeutics to Present Preliminary Data from the BRIGHT Study of pegunigalsidase alfa for the Treatment of Fabry Disease at the 15th Annual WORLDSymposium™ 2019

~Oral presentation to include pharmacokinetic and anti-drug antibody data for first 15 patients enrolled~ CARMIEL, Israel, Jan. 28, 2019 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE:PLX), a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx®, today announced that the Company will present preliminary pharmacokinetic (PK) dat...